Search This Blog

Wednesday, January 27, 2021

Stifel sticks to Buy on Rhythm Pharma

 Stifel analyst Derek C. Archilia reiterated a Buy rating on Rhythm Pharmaceuticals (NASDAQ: RYTM).

https://www.streetinsider.com/Analyst+Comments/Stifel+Reiterates+Buy+Rating+on+Rhythm+Pharmaceuticals+%28RYTM%29%2C+Remains+on+Select+List/17862789.html

Posted by at

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.

Subscribe to: Post Comments (Atom)